OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.952
+0.095 (5.11%)
Nov 22, 2024, 4:00 PM EST - Market closed
OS Therapies Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for OS Therapies stock has a target of 21, which predicts an increase of 975.87% from the current stock price of 1.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 3, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for OS Therapies is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +975.87% | Oct 3, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +975.87% | Sep 16, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +975.87% | Sep 3, 2024 |
Financial Forecast
Revenue This Year
561.00K
Revenue Next Year
56.10M
from 561.00K
Increased by 9,900.00%
EPS This Year
-1.16
from -0.74
EPS Next Year
1.50
from -1.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 1.2M | 115.5M | 33.9M |
| Avg | 561,000 | 56.1M | 26.9M |
| Low | n/a | n/a | 20.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 20,488.2% | -39.5% |
| Avg | - | 9,900.0% | -52.1% |
| Low | - | - | -64.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.49 | 3.20 | 0.45 |
| Avg | -1.16 | 1.50 | 0.22 |
| Low | -1.76 | -0.11 | - |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | -69.9% |
| Avg | - | - | -85.4% |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.